Consiglio Nazionale delle Ricerche-ko ikertzaileekin lankidetzan egindako argitalpenak (8)

2020

  1. Sarcoma treatment in the era of molecular medicine

    EMBO Molecular Medicine, Vol. 12, Núm. 11

2018

  1. Gene therapy approaches in the non-human primate model of Parkinson’s disease

    Journal of Neural Transmission, Vol. 125, Núm. 3, pp. 575-589

2017

  1. AAV-PHP.B-Mediated Global-Scale Expression in the Mouse Nervous System Enables GBA1 Gene Therapy for Wide Protection from Synucleinopathy

    Molecular Therapy, Vol. 25, Núm. 12, pp. 2727-2742

2014

  1. L-DOPA disrupts adenosine A2A-cannabinoid CB1-dopamine D2 receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: Biochemical and behavioral studies

    Experimental Neurology, Vol. 253, pp. 180-191

  2. L-DOPA-treatment in primates disrupts the expression of A2A adenosine-CB1 cannabinoid-D2 dopamine receptor heteromers in the caudate nucleus

    Neuropharmacology, Vol. 79, pp. 90-100

  3. Neuroprotective potential of adenosine A2A and cannabinoid CB1 receptor antagonists in an animal model of Parkinson disease

    Journal of Neuropathology and Experimental Neurology, Vol. 73, Núm. 5, pp. 414-424

2011

  1. Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson's disease

    Pharmacology and Therapeutics, Vol. 132, Núm. 3, pp. 280-299

2000

  1. Type II protein C deficiency: Identification and molecular modelling of two natural mutants with low anticoagulant and normal amidolytic activity

    British Journal of Haematology, Vol. 108, Núm. 2, pp. 265-271